Psoriasis patients more susceptible to COVID-19 May 17th 2021, 09.55

• Author: Dr David Ashton
• Topic: Coronavirus (COVID-19)

As the COVID-19 pandemic has continued, researchers have been able to study individual groups of patients with pre-existing medical conditions – including psoriasis.  One especially important question, is whether patients diagnosed with psoriasis, could be more at risk of infection with COVID-19?  

In a recent (virtual) meeting of the American…

Biologics may reduce the risk of heart disease Dec 10th 2020, 13.31

• Author: Dr David Ashton
• Topic: Treatment

Encouraging new evidence suggests that biological treatment for psoriasis, may reduce the risk of coronary heart disease. 

Biologics have been used in the treatment of psoriasis since the early 2000s.  They block the actions of various inflammatory molecules – cytokines – which play a major role in the development of psoriasis and psoriatic…

Systemic drug therapy in the obese patient with psoriasis Nov 8th 2020, 13.37

• Author: Dr David Ashton
• Topic: Psoriasis

Should a patient’s Body Mass Index (BMI) influence the choice of a systemic drug in the treatment of psoriasis and psoriatic arthritis?  A recent report suggests that the answer is ‘Yes’¹.

There is a strong and consistent association between obesity and psoriasis; obese patients are more likely to develop psoriasis and its severity increases with…

COVID-19 updated guidance on shielding Oct 26th 2020, 11.13

• Author: David Chandler
• Topic: Coronavirus (COVID-19)

Clinically extremely vulnerable groups

With the changing COVID-19 restrictions, you may like to know what the definition of clinically extremely vulnerable groups are

People who are defined as clinically extremely vulnerable are at very high risk of severe illness from coronavirus. There are 2 ways you may be identified as clinically extremely…